These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6520783)

  • 1. Pharmacokinetic implications of stereoselective changes in plasma-protein binding: warfarin/sulfinpyrazone.
    Toon S; Trager WF
    J Pharm Sci; 1984 Nov; 73(11):1671-3. PubMed ID: 6520783
    [No Abstract]   [Full Text] [Related]  

  • 2. Warfarin-sulfinpyrazone interaction on binding to human serum albumin.
    Larsen FG; Larsen CG; Brodersen R
    J Pharm Pharmacol; 1984 Oct; 36(10):689-90. PubMed ID: 6150088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereoselective interaction of sulfinpyrazone with racemic warfarin and its separated enantiomorphs in man.
    O'Reilly RA
    Circulation; 1982 Jan; 65(1):202-7. PubMed ID: 7053283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative interaction of sulfinpyrazone and phenylbutazone with racemic warfarin: alteration in vivo of free fraction of plasma warfarin.
    O'Reilly RA; Goulart DA
    J Pharmacol Exp Ther; 1981 Dec; 219(3):691-4. PubMed ID: 7299692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding of sulfinpyrazone and its metabolites in human serum and in solutions of human serum albumin.
    Jakobsen P; Pedersen AK; Andreasen F
    Acta Pharmacol Toxicol (Copenh); 1982 Sep; 51(3):243-9. PubMed ID: 7136730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of heparin and fatty acids on the binding of quinidine and warfarin in plasma.
    Nilsen OG; Storstein L; Jacobsen S
    Biochem Pharmacol; 1977 Feb; 26(3):229-35. PubMed ID: 843392
    [No Abstract]   [Full Text] [Related]  

  • 7. The warfarin-sulfinpyrazone interaction: stereochemical considerations.
    Toon S; Low LK; Gibaldi M; Trager WF; O'Reilly RA; Motley CH; Goulart DA
    Clin Pharmacol Ther; 1986 Jan; 39(1):15-24. PubMed ID: 3943265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced warfarin binding of albumin variants.
    Wilding G; Blumberg ES; Vesell ES
    Science; 1977 Mar; 195(4282):991-4. PubMed ID: 841323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma protein binding of phenytoin and warfarin in patients undergoing renal transplantation.
    Odar-Cederlof I
    Clin Pharmacokinet; 1977; 2(2):147-53. PubMed ID: 324689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereoselective binding of the enantiomers of warfarin and tryptophan to serum albumin from some different species studied by affinity chromatography on columns of immobilized serum albumin.
    Lagercrantz C; Larsson T; Denfors I
    Comp Biochem Physiol C Comp Pharmacol; 1981; 69(2):375-8. PubMed ID: 6116580
    [No Abstract]   [Full Text] [Related]  

  • 11. Binding of fluvastatin to blood cells and plasma proteins.
    Tse FL; Nickerson DF; Yardley WS
    J Pharm Sci; 1993 Sep; 82(9):942-7. PubMed ID: 8229693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALTERATION OF THE ACETYLATION OF SULFONAMIDES BY PROTEIN BINDING, SULFINPYRAZONE, AND SURAMIN.
    ANTON AH; BOYLE JJ
    Can J Physiol Pharmacol; 1964 Nov; 42():809-17. PubMed ID: 14324214
    [No Abstract]   [Full Text] [Related]  

  • 13. Consequences of the N-B transition of albumin for the binding of warfarin in human serum.
    van der Giesen WF; Wilting J
    Biochem Pharmacol; 1983 Jan; 32(2):281-5. PubMed ID: 6870956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of sulfinpyrazone on the disposition of pseudoracemic phenprocoumon in humans.
    Heimark LD; Toon S; Gibaldi M; Trager WF; O'Reilly RA; Goulart DA
    Clin Pharmacol Ther; 1987 Sep; 42(3):312-9. PubMed ID: 3621786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of phenylbutazone, tolbutamide, and clofibric acid on binding of racemic warfarin and its enantiomers to human serum albumin.
    Veronich K; White G; Kapoor A
    J Pharm Sci; 1979 Dec; 68(12):1515-8. PubMed ID: 529041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of some physico-chemical properties of human serum albumin samples from different sources--II. The characteristics of the N-B transition and the binding behaviour with regard to warfarin and diazepam.
    Dröge JH; Wilting J; Janssen LH
    Biochem Pharmacol; 1982 Dec; 31(23):3781-6. PubMed ID: 7159460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enantioselective structure-pharmacokinetic relationships of ring substituted warfarin analogues in the rat.
    Baars LG; Schepers MT; Hermans JJ; Dahlmans HJ; Thijssen HH
    J Pharm Pharmacol; 1990 Dec; 42(12):861-6. PubMed ID: 1983149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics and clinical importance of displacement of warfarin from albumin by acidic drugs.
    Sellers EM; Koch-Weser J
    Ann N Y Acad Sci; 1971 Jul; 179():213-25. PubMed ID: 5285376
    [No Abstract]   [Full Text] [Related]  

  • 19. Binding of indomethacin to human serum albumin. Its non displacement by various agents, influence of free fatty acids and the unexpected effect of indomethacin on warfarin binding.
    Zini R; D'Athis P; Barre J; Tillement JP
    Biochem Pharmacol; 1979 Sep; 28(17):2661-5. PubMed ID: 518678
    [No Abstract]   [Full Text] [Related]  

  • 20. Stereoselective kinetics of warfarin binding to human serum albumin: effect of an allosteric interaction.
    Fitos I; Visy J; Kardos J
    Chirality; 2002 May; 14(5):442-8. PubMed ID: 11984760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.